


A Comprehensive Board Review in Hematology and Medical Oncology

—A Virtual Live Streaming Course—

August 19-24, 2024

August 19-23, 2024
Solid Tumors and Malignant Hematology

August 22-24, 2024
Malignant and Classical (Benign) Hematology



Baylor
College of
Medicine

THE UNIVERSITY OF TEXAS
MD Anderson
Cancer Center
Making Cancer History®

A Comprehensive Board Review in Hematology and Medical Oncology

— A Virtual Live Streaming Course —

GOAL

The course is a 6-day comprehensive review of current standards and practices in the management of patients with blood disorders and solid tumors. The course is designed to enable the participant to effectively prepare for the American Board of Internal Medicine certification and recertification examinations in Hematology and Medical Oncology. Advances in clinical pharmacology, molecular genetics and risk assessment, and radiation oncology will be included.

EDUCATIONAL OBJECTIVES

At the conclusion of this educational activity, participants should be able to:

- Apply knowledge gained to prepare for the hematology and medical oncology subspecialty and recertification examinations.
- Utilize current standards of care for patients with blood disorders and solid tumors.
- Demonstrate proficiency of knowledge in hematology and medical oncology.
- Incorporate recent advances in management of hematologic and oncologic patients.
- Define molecular determinants of cancer risk and apply this knowledge in practice.

TARGET AUDIENCE

This program should be of interest to Physicians, Advanced Practice Providers, and Advanced Practice Registered Nurses.

EDUCATIONAL METHODS

- Lectures/Didactic
- Case-based Question-and-Answer Sessions (in board examination format)
- Virtual Live Streaming Course
- Canvas – an online course management system

EVALUATION

An online course evaluation tool will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

ACCREDITATION



JOINTLY ACCREDITED PROVIDER
INTERNATIONAL CONTINUING EDUCATION

In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 50.00 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC POINTS

American Board of Internal Medicine



Successful completion of this CE activity, which includes participation in the evaluation component, enables the participant to earn up to 50.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CE credits claimed for the activity.

It is the CE activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points. In order to receive MOC points, you must pass the post-test with a score of 70% or higher.

CE CERTIFICATES AND ATTENDANCE VERIFICATION CERTIFICATES

Certificates awarding *AMA PRA Category 1 Credit™* or certificates documenting attendance will be available to participants once they complete the on-line evaluation. To obtain a CE certificate, physicians must complete the on-line evaluation questionnaire.

A record of attendance (certificate) will be available online to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.

PLANNING COMMITTEE

MD Anderson Cancer Center

Sharon Giordano, MD, MPH, Co-Director

Tapan Kadia, MD, Co-Director

Shreyaskumar Patel, MD

Alessandra Ferrajoli, MD

Nishin Bhadkamkar, MD

Felisha Estelle

Baylor College of Medicine

Martha Mims, MD, PhD, Co-Director

AGENDA

Monday, August 19, 2024

All times are in Central Daylight Time (CDT)

7 a.m. Virtual Online Registration Check-in

SOLID TUMOR SESSION

Genitourinary Oncology | Melanoma

- 7:30 a.m. **Testicular Cancer**
Timothy Gilligan, MD
- 8:30 a.m. **Urothelial Cancer**
Arlene Siefker-Radtke, MD
- 9:15 a.m. **Renal Cell Carcinoma**
Eric Jonasch, MD
- 10 a.m. Break
- 10:15 a.m. **Prostate Cancer**
Brad Carthon, MD
- 11:15 a.m. **Melanoma**
Rodabe Amaria, MD
- 12 p.m. **Q & A Panel Discussion**
Timothy Gilligan, MD; Arlene Siefker-Radtke, MD;
Eric Jonasch, MD; Brad Carthon, MD; and
Rodabe Amaria, MD
- 12:15 p.m. Lunch Break

Gastrointestinal Oncology

- 12:45 p.m. **Pancreaticobiliary Cancers/Unknown Primary**
Robert Wolff, MD
- 1:45 p.m. **Gastroesophageal Cancers/Hepatocellular Carcinoma**
Harry Yoon, MD
- 2:45 p.m. Break
- 3 p.m. **Colorectal Cancer: Biology and Adjuvant Therapy**
Scott Kopetz, MD, PhD
- 3:30 p.m. **Metastatic Colorectal Cancer and Anal Cancer**
Scott Kopetz, MD, PhD
- 4:30 p.m. **Q & A Panel Discussion**
Robert Wolff, MD; Harry Yoon, MD;
and Scott Kopetz, MD, PhD
- 4:45 p.m. **Solid Tumor Q & A - Session 1: Genitourinary Oncology/Gastrointestinal Oncology/ Melanoma**
Megan Dupuis, MD, PhD
- 5:25 p.m. Adjourn

Tuesday, August 20, 2024

All times are in Central Daylight Time (CDT)

7 a.m. Virtual Online Registration Check-in

Pharmacology | Genetic Risk Factors | Sarcoma

- 7:30 a.m. **Pharmacology I: Chemotherapy**
Claire Mach, PharmD
- 8:30 a.m. **Pharmacology II: Targeted Therapy (ALK, EGFR, VEGF, HER2, HH, mTOR)**
Whitney Lewis, PharmD
- 9 a.m. Break
- 9:10 a.m. **Pharmacology III: Targeted Therapy (CD20, CD30, CD33, Proteasome, BCR-ABL/KIT, FLT3, IDH1/2, CDK4/6, P13K)**
Brian Primeaux, PharmD
- 9:40 a.m. **Pharmacology IV: Immunotherapy**
Claire Mach, PharmD
- 10 a.m. Break
- 10:15 a.m. **Genetic Risk Factors**
Claudine Isaacs, MD
- 11 a.m. **Sarcoma**
Shreyaskumar Patel, MD
- 12 p.m. **Q & A Panel Discussion**
Claire Mach, PharmD; Whitney Lewis, PharmD;
Brian Primeaux, PharmD; Claudine Isaacs, MD;
and Shreyaskumar Patel, MD
- 12:15 p.m. Lunch Break
- ### Breast Cancer
- 12:45 p.m. **Screening/Local Management of Breast Cancer**
Abenaa Brewster, MD
- 1:30 p.m. **Systemic Treatment of Early-Stage Breast Cancer**
Sharon Giordano, MD
- 2:30 p.m. Break
- 2:45 p.m. **Treatment of Metastatic Breast Cancer**
Mariana Chavez MacGregor, MD
- 3:45 p.m. **Special Issues in Breast Cancer**
Jennifer Litton, MD
- 4:15 p.m. **Q & A Panel Discussion**
Abenaa Brewster, MD; Sharon Giordano, MD;
Mariana Chavez MacGregor, MD; and
Jennifer Litton, MD
- 4:30 p.m. **Solid Tumor Q & A - Session 2: Pharmacology/ Genetic Risk Factors/Sarcoma/ Breast Cancer**
Mark Lewis, MD
- 5:10 p.m. Adjourn

Wednesday, August 21, 2024

All times are in Central Daylight Time (CDT)

7 a.m. Virtual Online Registration Check-in

Lung Cancer | Head and Neck Cancer | Thyroid Cancer

7:30 a.m. **Early Stage and Locally Advanced Non-Small Cell Lung Cancer**
Nasser Hanna, MD

8:15 a.m. **Metastatic Non-Small Cell Lung Cancer**
Nasser Hanna, MD

9:15 a.m. **Small Cell Lung Cancer**
Carl Gay, MD

9:45 a.m. Break

10 a.m. **Head and Neck Cancer**
William N. William, Jr., MD

10:45 a.m. **Thyroid Cancer**
Mimi Hu, MD

11:15 a.m. **Q & A Panel Discussion**
Nasser Hanna, MD; Carl Gay, MD;
William N. William, Jr., MD; and Mimi Hu, MD

11:30 a.m. **ASH/ASCO Choosing Wisely Recommendations**
Ravin Garg, MD

12:10 p.m. Lunch Break

Neuro-Oncology | Gynecologic Oncology

1 p.m. **Neuro-Oncology**
Antonio Omuro, MD

1:45 p.m. **Cervical Cancer**
Alejandro Rauh Hain, MD

2:30 p.m. Break

2:45 p.m. **Uterine Cancer**
Ramez Eskander, MD

3:15 p.m. **Ovarian Cancer and Unusual Ovarian Histologies**
Emily Hinchcliff, MD, MPH

4:15 p.m. **Q & A Panel Discussion**
Antonio Omuro, MD; Ramez Eskander, MD;
Emily Hinchcliff, MD, MPH; and
Alejandro Rauh Hain, MD

4:30 p.m. **Solid Tumor Q & A – Session 3: Lung Cancer/
Head Neck Cancer/Thyroid Cancer/
Neuro-Onc/Gynecologic Oncology**
Ravin Garg, MD

5:10 p.m. Adjourn

Thursday, August 22, 2024

All times are in Central Daylight Time (CDT)

7 a.m. Virtual On-line Registration Check-in

MALIGNANT HEMATOLOGY SESSION

Lymphoma | Myeloma

7:30 a.m. **Classification of Lymphoma**
Jeffrey Medeiros, MD

8:15 a.m. **Aggressive Non-Hodgkin Lymphoma**
Christopher Flowers, MD

9 a.m. **Indolent Non-Hodgkin Lymphoma**
Carla Casulo, MD

9:45 a.m. Break

10 a.m. **Hodgkin Lymphoma**
Alison Moskowitz, MD

10:45 a.m. **Multiple Myeloma and Other Plasma Cell Dyscrasias**
S. Vincent Rajkumar, MD

11:45 a.m. **Q & A Panel Discussion**
Jeffrey Medeiros, MD; Christopher Flowers, MD;
Carla Casulo, MD; Alison Moskowitz, MD; and
S. Vincent Rajkumar, MD

12 p.m. Lunch Break

Leukemia | MDS

12:30 p.m. **Chronic Myeloid Leukemia**
Jorge Cortes, MD

1:15 p.m. **Myelodysplastic Syndrome**
Tapan Kadia, MD

2:15 p.m. **Infectious Complications in Cancer Patients**
Samuel Shelburne, MD, PhD

3:15 p.m. Break

3:30 p.m. **Acute Lymphoblastic Leukemia**
Hagop Kantarjian, MD

4:15 p.m. **Q & A Panel Discussion**
Jorge Cortes, MD; Tapan Kadia, MD;
Samuel Shelburne, MD, PhD; and Hagop Kantarjian, MD

4:30 p.m. **Malignant Hematology Q & A Session**
Patrick Reville, MD

5:10 p.m. Adjourn

Friday, August 23, 2024

All times are in Central Daylight Time (CDT)

7 a.m. Virtual Online Registration Check-in

Leukemia | MPN | SCT

- 7:30 a.m. **Chronic Lymphocytic Leukemia and Hairy Cell Leukemia**
Susan O'Brien, MD
- 8:15 a.m. **Myeloproliferative Neoplasms**
Raajit Rampal, MD, PhD
- 9:15 a.m. Break
- 10 a.m. **Acute Myeloid Leukemia**
Courtney DiNardo, MD
- 11 a.m. **Stem Cell Transplant Supportive Care**
Betty Hamilton, MD
- 12 p.m. **Q & A Panel Discussion**
Susan O'Brien, MD; Raajit Rampal, MD, PhD;
Courtney DiNardo, MD; and Betty Hamilton, MD
- 12:15 p.m. Lunch Break

CLASSICAL (BENIGN) HEMATOLOGY SESSION

General Topics | Red Cell Disorders | Platelets

- 1 p.m. **Iron Deficiency and Hemochromatosis**
Matthew Heeney, MD
- 1:45 p.m. **Hematopoietic Growth Factors**
Martha Mims, MD, PhD
- 2:30 p.m. **Bone Marrow Failure**
Timothy Olson, MD, PhD
- 3:15 p.m. Break
- 3:30 p.m. **Leukopenia and Leukocytosis**
Nancy Berliner, MD
- 4:15 p.m. **Hemolytic Anemias**
Gerald Soff, MD
- 5:15 p.m. **Q & A Panel Discussion**
Matthew Heeney, MD; Martha Mims, MD, PhD;
Timothy Olson, MD, PhD; Nancy Berliner, MD;
and Gerald Soff, MD
- 5:30 p.m. Adjourn

Saturday, August 24, 2024

All times are in Central Daylight Time (CDT)

7 a.m. Virtual On-line Registration Check-in

Coagulation | Platelets | Red Cell Disorders

- 7:30 a.m. **Sickle Cell Anemias, Thalassemia, and Hemoglobinopathies**
Alice Ma, MD
- 8:15 a.m. **Issues in Transfusion Medicine**
Kerry O'Brien, MD
- 9 a.m. **Approach to Anemia**
Alice Ma, MD
- 9:30 a.m. Break
- 9:45 a.m. **Disorders of Platelet Function**
A. Koneti Rao, MD, FACP
- 10:30 a.m. **Thrombocytopenias**
Alfred Lee, MD, PhD
- 11:15 a.m. **Q & A Panel Discussion**
Alice Ma, MD; Kerry O'Brien, MD;
A. Koneti Rao, MD, FACP; and Alfred Lee, MD, PhD
- 11:30 a.m. Lunch Break

Platelets | Red Cell Disorders | Transfusion Medicine

- 12:15 p.m. **Benign Heme Q & A Session**
Senthil Sukumar, MD
- 1 p.m. **Antithrombotic & Antiplatelet Therapy**
Bethany Samuelson, MD
- 1:45 p.m. **Normal Coagulation**
Kenneth Bauer, MD
- 2:30 p.m. Break
- 2:45 p.m. **Coagulation Factor Deficiencies, Including von Willebrand's Disease and Hemophilias**
Kenneth Bauer, MD
- 3:30 p.m. **Hypercoagulable States**
Stephan Moll, MD
- 4:15 p.m. **Q & A Panel Discussion**
Senthil Sukumar, MD; Bethany Samuelson, MD;
Kenneth Bauer, MD; and Stephan Moll, MD
- 4:30 p.m. Adjourn

Guest Faculty

Bethany Samuelson Bannow, MD, MCR
Oregon Health & Science University
Portland, Oregon

Kenneth Bauer, MD
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Nancy Berliner, MD
Brigham and Women's Hospital
Boston, Massachusetts

Bradley Carthon, MD, PhD
Emory Healthcare
Atlanta, Georgia

Carla Casulo, MD
James P. Wilmot Cancer Institute
University of Rochester
Rochester, New York

Jorge Cortes, MD
Georgia Cancer Center
Augusta, Atlanta

Megan Dupuis, MD, PhD
Vanderbilt-Ingram Cancer Center
Lebanon, Tennessee

Ramez Eskander, MD
UC San Diego Health
International Patient Program
San Diego, California

Ravin Garg, MD
Johns Hopkins University Maryland
Oncology Hematology -
Annapolis Division
Annapolis, Maryland

Timothy Gilligan, MD
Cleveland Clinic
Cleveland, Ohio

Betty Hamilton, MD
Cleveland Clinic
Cleveland, Ohio

Nasser Hanna, MD
Indiana University School of Medicine
Indianapolis, Indiana

Matthew Heeney, MD
Dana-Farber/Boston Children's Cancer
and Blood Disorders Center
Boston, Massachusetts

Emily Hinchcliff, MD, MPH
Northwestern Medicine
Chicago, Illinois

Claudine Isaacs, MD
Georgetown University
Washington, District of Columbia

Alfred Lee, MD, PhD
Yale School of Medicine
New Haven, Connecticut

Mark Lewis, MD
Intermountain Healthcare
Murray, Utah

Alice Ma, MD
University of North Carolina -
Chapel Hill School of Medicine
Chapel Hill, North Carolina

Stephan Moll, MD
University of North Carolina School
of Medicine
Chapel Hill, North Carolina

Alison Moskowitz, MD
Memorial Sloan Kettering Cancer Center
New York, New York

Kerry O'Brien, MD
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Susan O'Brien, MD
University of California, Irvine
Irvine, California

Timothy Olson, MD, PhD
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania

Antonio Omuro, MD
Yale Cancer Center
New Haven, Connecticut

S. Vincent Rajkumar, MD
Mayo Clinic - Minnesota
Rochester, Minnesota

Raajit Rampal, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, New York

A. Koneti Rao, MD, FACP
Lewis Katz School of Medicine
at Temple University
Philadelphia, Pennsylvania

Gerald Soff, MD
University of Miami Health System/
Sylvester Comprehensive Cancer Center
Miami, Florida

William William, Jr., MD
BP Hospital
Sao Paulo, Brazil

Harry Yoon, MD
Mayo Clinic - Minnesota
Rochester, Minnesota

REGISTRATION INFORMATION

A Virtual Live Streaming Course

The Comprehensive Board Review in Hematology and Medical Oncology will be virtual. This program will be presented only as a live streaming course. You will receive an email from the course platform to log in and access the live course online approximately 3 days before the conference.

PRESENTATIONS:

The presentations will be pre-recorded. The speakers will be available for the live Q&A sessions. Course syllabus will not be printed. Presentations (slides) will be available online via the course platform and Canvas. The PowerPoint presentations will be posted online as PDFs prior to the conference. You will receive an invitation email with directives to log in Canvas after the conference adjourns.

- **The Full Conference and Oncology Session** will begin at 7:30 a.m. on Monday, August 19. The Oncology Session will adjourn at 12:15 p.m. on Friday, August 23, 2024.
- **The Hematology Session** will begin at 7:30 a.m. on Thursday, August 22 and adjourn at 4:30 p.m. on Saturday, August 24.

Advanced registration is encouraged. Please see the online registration fees page.

***NOTE: The conference registration fee includes the tuition, access to course virtual platform with PDFs of the slides and Canvas - online web-based system with recorded videos.**

The deadline for advanced registration is Monday, August 5, 2024.

- Register online at <https://mdanderson.cloud-cme.com/HMOBR2024>

Telephone registrations are not accepted.

We accept the following forms of payment:

- Credit Cards (MasterCard, VISA, and American Express)
- Check (payable through U.S. banks only)
- **Mail to:** Continuing Professional Education – Unit 1781
The University of Texas MD Anderson Cancer Center
P.O. Box 301407
Houston, TX 77230-1407

When registering online a receipt (confirmation letter) will be automatically emailed to the e-mail address you list on the registration form.

REFUND/CANCELLATION POLICY

The registration fee, minus a \$50 administrative handling fee, is refundable if a written request is received on or before **Monday, August 5, 2024**. No refunds will be granted after that date. The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check. For additional information, contact Continuing Professional Education at 713-792-2223 or toll free at 866-849-5866.

Continuing Professional Education reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified by mail, e-mail, or at the phone or fax numbers given on the registration form.

In case of activity cancellation, the liability of Continuing Professional Education is limited to the registration fee. Continuing Professional Education will refund the full registration fee.

Continuing Professional Education reserves the right to limit the number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available. Please check the website.

PAST CONFERENCES - REVIEWS AND TESTIMONIALS

“The conference was well worth my time. It is nice to be able to take in as much information as possible and have the option of talking to the speakers afterwards. If this board review is still around in ten years (I hope it is), I will certainly attend it again as I study for my recertification.”

“Fantastic course! It helped pass my boards with flying colors!”

“As a first time attendee and visitor to MD Anderson, the overall organization and quality of activity was very impressive and met every expectation. Would recommend this activity to any colleague/associate.”

“Excellent review course. The conference was well organized and ran smoothly.”

“Exceeded expectations; worth every penny.”

“Superb conference. Exceptional, impressive”

“Very well organized. Amazing how well support staff kept program on time.”

Please let us know what specific topics, issues, or questions you wish to see addressed or emphasized in this activity by emailing Continuing Professional Education at ContinuingEducation@mdanderson.org. All responses will be forwarded to the Course Directors for consideration.

SPECIAL ASSISTANCE

Contact Felisha Estelle in Continuing Professional Education at 713-745-0083 or 1-866-531-MOBR (6627) if you have any ADA accommodation needs.

CONFERENCE REGISTRATION - D128821

Comprehensive Board Review in Hematology and Medical Oncology

August 19-24, 2024

CONFERENCE REGISTRATION FEES

Full Conference - MDs, PhDs, DOs, PharmDs

- Postmarked on or before July 22, 2024 \$1,200
- Postmarked on or before August 5, 2024. \$1,300
- Postmarked after August 5, 2024. \$1,400

Full Conference - Residents/Fellows/MD Anderson Alumni*

- Postmarked on or before July 22, 2024 \$800
- Postmarked on or before August 5, 2024 \$900
- Postmarked after August 5, 2024. \$1,000

Oncology Session - 4 ½ days (Monday - Friday A.M.)

MDs, PhDs, DOs, PharmDs

- Postmarked on or before July 22, 2024 \$650
- Postmarked on or before August 5, 2024 \$700
- Postmarked after August 5, 2024. \$750

Oncology Session - 4 ½ days (Monday - Friday A.M.)

Residents/Fellows/MD Anderson Alumni*

- Postmarked on or before July 22, 2024 \$450
- Postmarked on or before August 5, 2024 \$500
- Postmarked after August 5, 2024. \$550

Hematology Session - 3 days (Thursday - Saturday)

MDs, PhDs, DOs, PharmDs

- Postmarked on or before July 22, 2024 \$550
- Postmarked on or before August 5, 2024 \$600
- Postmarked After August 5, 2024 \$650

Hematology Session - 3 days (Thursday - Saturday)

Residents/Fellows/MD Anderson Alumni*

- Postmarked On Or Before July 22, 2024 \$350
- Postmarked On Or Before August 5, 2024 \$400
- Postmarked after August 5, 2024. \$450

-
- Advanced Practice Providers/Advanced Practice Registered Nurses* . . . \$450
 - MD Anderson/Baylor Faculty/Staff \$500
 - MD Anderson/Baylor Clinical Fellows* Exempt

*A letter of introduction from the program director or chairperson with registration form is required to claim this reduced fee.

Make check payable to:

The University of Texas MD Anderson Cancer Center

2024 HEMATOLOGY AND MEDICAL ONCOLOGY BOARD REVIEW: COMPREHENSIVE PROGRAM MATERIAL AVAILABLE FOR NON-ATTENDEES

Comprehensive source material can provide you with home-study material designed for fellows-in-training, physicians planning to take the Hematology or Medical Oncology certifying examination, or physicians wishing to review the established standards of care in Hematology or Medical Oncology.

The conference registration fee includes the tuition, access to the course virtual platform with PDFs of the slides and Canvas (online web-based system with recorded videos).

NOTE: The conference will be available through an online course management system (Canvas) where you will be able to view each recorded lecture. The full conference will be available approximately 12 days after the conference adjourns. Instructions for access to Canvas will be provided.

CE Credits and MOC Points are awarded only by attending the virtual live course. Credits and points can not be awarded for watching the on-demand videos after the course has adjourned.

Available option to obtain course material:

**CANVAS - online web-based system with recorded videos
(Log in instructions will be provided)**

- Online site with downloadable audio & videos for the entire 2024 course
- Each speaker's complete PowerPoint slide presentation (Adobe Acrobat PDF file)
- Full color, just as presented
- Each speaker's list of references
- Please allow 3-5 business days to process order before receiving log in instructions

D128822/PS118825

NON ATTENDEES

CANVAS - online system with recorded videos..... \$1,000.00

Telephone orders are not accepted.

Register online at <https://mdanderson.cloud-cme.com/HMOBR2024>

ALL SALES ARE FINAL.

Make check or money order payable to: The University of Texas MD Anderson Cancer Center. Please allow 3-5 business days to process order before receiving log in instructions.



The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented.

MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, scheduling conflicts, and so forth.

Photographing, audio taping and videotaping are prohibited.

The University of Texas MD Anderson Cancer Center
Continuing Professional Education - Unit 1781
176700/30/128821/41
P.O. Box 301407
Houston, Texas 77230-1407

Non-Profit Org.
U.S. Postage
PAID
Houston, TX
Permit No. 7052